Idorsia Pharmaceuticals Ltd, headquartered in Allschwil, Switzerland, is dedicated to the discovery and development of innovative pharmaceutical compounds. The company specializes in a range of therapeutic areas, focusing on PGE2 receptor modulators, CXCR7 receptor antagonists, and various derivatives aimed at treating conditions such as fibrosis and bacterial infections. Idorsia's commitment to advancing medical science is reflected in its extensive research into calcium channel blockers and other novel compounds, positioning it as a key player in the pharmaceutical industry.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

81 Patents

#2 in Allschwil

#198 in Switzerland

#9,354 in the World

Allschwil, Switzerland

Idorsia Pharmaceuticals Ltd

Forward Citations = 142

118 inventors:

Christoph Boss (16 out of 59 patents)

Martin Bolli (15 out of 66 patents)

Markus Von Raumer (13 out of 16 patents)

4. Bibia Heidmann (12 out of 21 patents)

5. Thierry Sifferlen (12 out of 40 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Idorsia Pharmaceuticals Ltd. Retrieved from https://idiyas.com/company/idorsia-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

18 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

66 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]